US Patent

US9066913 — Diclofenac topical formulation

Method of Use · Assigned to HZNP Ltd · Expires 2027-10-17 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a gel formulation of diclofenac sodium for topical treatment of pain, such as in osteoarthritis.

USPTO Abstract

The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.

Drugs covered by this patent

Arthrotec (Diclofenac Sodium) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1488`	—	Arthrotec

Patent Metadata

Patent number: US9066913
Jurisdiction: US
Classification: Method of Use
Expires: 2027-10-17
Drug substance claim: No
Drug product claim: Yes
Assignee: HZNP Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.